Trial Profile

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epcoritamab (Primary)
Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions; Pharmacokinetics
Acronyms EPCORE Peds-1
Sponsors Genmab

Most Recent Events

04 Apr 2025 Status changed from recruiting to active, no longer recruiting.
03 Dec 2024 Planned End Date changed from 27 Nov 2028 to 1 Nov 2028.
03 Dec 2024 Planned primary completion date changed from 18 Jun 2027 to 1 Nov 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com